chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 37.0
Sex: F
Vaccine: FLUX
Symptoms: Pain, Skin warm, Urticaria
Clinical narrative: Pain at injection site which turned into my arm being covered in large red hot painful welts. They don't itch, but feel bruised. I am also now nauseous and have a bad headache. Waiting to see my doctor on Monday.
Age: 50.0
Sex: F
Vaccine: VARZOS
Symptoms: Injection site pruritus, Injection site reaction, Rash erythematous
Clinical narrative: On 10/05/2016 presented with photos of large red rash on left tricep where shot was administered. She complained of itching,too. No rash seen on that date.
Age: 45.0
Sex: F
Vaccine: FLUX
Symptoms: Back pain, Neuralgia
Clinical narrative: Back pain; no comfortable position; spread out like fingers from spine, mostly of left side creeping toward flank. No treatment available until Monday when my dr office opens. Believe it is reactivation of Shingles. No rash hx for chicken pox nor shingles, but terrible nerve pain that did not cross mid-line.
Age: 74.0
Sex: F
Vaccine: VARZOS, VARZOS, FLU3, VARZOS
Symptoms: Erythema, Pruritus, Rash generalised
Clinical narrative: Patient complains of rash-like symptoms all over her body but specifically in the mid-section. She has contacted her primary care physician who has since prescribed for her steroid cream to be used on the area of redness/itching.
Age: 74.0
Sex: F
Vaccine: VARZOS, VARZOS, FLU3, VARZOS
Symptoms: Incorrect route of drug administration, Pulmonary physical examination, Rash, Rash morbilliform, Urticaria
Clinical narrative: Patient complains of rash-like symptoms all over her body but specifically in the mid-section. She has contacted her primary care physician who has since prescribed for her steroid cream to be used on the area of redness/itching.
Age: 74.0
Sex: F
Vaccine: VARZOS, VARZOS, FLU3, VARZOS
Symptoms: Rash morbilliform, Urticaria
Clinical narrative: Patient complains of rash-like symptoms all over her body but specifically in the mid-section. She has contacted her primary care physician who has since prescribed for her steroid cream to be used on the area of redness/itching.
Age: 11.0
Sex: M
Vaccine: HPV9
Symptoms: Blood pressure abnormal, Dizziness, Hyperhidrosis, Syncope
Clinical narrative: I was called into the room and notified that 4 minutes after he received his HPV vaccine, he became sweaty, dizzy, and fainted.  His airway, breathing, and circulation were intact.  He was oriented to person, place, and time but had initial blood pressure of 74/45 that improved after 15 minutes of lying down to 105/65.
Age: 85.0
Sex: F
Vaccine: FLU3
Symptoms: Injection site erythema, Injection site pruritus
Clinical narrative: Red patch on arm below vaccination site that was itchy.
Age: 11.0
Sex: F
Vaccine: FLUX, HPV9, MEN, TDAP
Symptoms: Head injury, Headache, Syncope
Clinical narrative: Fainted within 10 minutes of receiving Tdap, Meningococcal, GARDASILl-9, and Influenza vaccines.  Was allowed to leave office immediately after receiving vaccines.  Fainted in hallway while leaving office.  Hit head on floor.  Brought back into physican's office for observation.  Back of head sore but not swelling.  Vomited approximately 2 hours after falling and again 3 hours after fall.
Age: 60.0
Sex: F
Vaccine: FLU4
Symptoms: Cough, Dysphonia, Eye pruritus, Fatigue, Headache
Clinical narrative: Sore at injection site, hoarse, red itchy eyes, cough, aches, headache, fatigue.
Age: 60.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site pain, Ocular hyperaemia, Pain
Clinical narrative: Sore at injection site, hoarse, red itchy eyes, cough, aches, headache, fatigue.
Age: 73.0
Sex: F
Vaccine: FLU4
Symptoms: Vomiting
Clinical narrative: Vomiting.
Age: 65.0
Sex: M
Vaccine: PPV
Symptoms: Chills, Pain in extremity, Pyrexia
Clinical narrative: Excruciating pain in arm and fever chills.
Age: 36.0
Sex: F
Vaccine: FLU4, FLU4
Symptoms: Asthenia, Dyspnoea, Feeling hot, Nausea, Pallor
Clinical narrative: Nausea, could not get air, overheated, could not hold self up.
Age: 36.0
Sex: F
Vaccine: FLU4, FLU4
Symptoms: Tremor
Clinical narrative: Nausea, could not get air, overheated, could not hold self up.
Age: 36.0
Sex: F
Vaccine: FLU4, FLU4
Symptoms: Dyspnoea, Erythema
Clinical narrative: Nausea, could not get air, overheated, could not hold self up.
Age: 64.0
Sex: F
Vaccine: FLUC4
Symptoms: Dizziness, Heart rate increased, Nausea
Clinical narrative: Heart beating fast, no appetite, light-headed, queasiness. 10/6/2016 8:00 AM: VERY light-headed, dizzy, nauseated, felt like I might faint when standing. This lasted all day into evening. When I awoke next morning, it was all gone.
Age: 30.0
Sex: F
Vaccine: FLU4
Symptoms: Injection site erythema, Injection site pruritus
Clinical narrative: Patient reports redness and itching around the injection site for one week following injection, denies pain or purulent discharge, denies swelling.
Age: 34.0
Sex: F
Vaccine: FLUX
Symptoms: Injection site reaction, Muscular weakness
Clinical narrative: Full arm weakness in arm of injection.  No medical help or treatment sought yet.
Age: 59.0
Sex: F
Vaccine: FLU4, PPV
Symptoms: Dizziness, Injection site erythema, Lethargy, Lymphadenopathy, Pain
Clinical narrative: Patient described having welts, redness at the injection site, pain, swollen glands, dizziness  and lethargy.  Patient did not report to pharmacy unitl 10/15/2016.  Told patient to follow up with their physician since still red and hot to the touch.
Age: 59.0
Sex: F
Vaccine: FLU4, PPV
Symptoms: Skin warm, Urticaria
Clinical narrative: Patient described having welts, redness at the injection site, pain, swollen glands, dizziness  and lethargy.  Patient did not report to pharmacy unitl 10/15/2016.  Told patient to follow up with their physician since still red and hot to the touch.
Age: 60.0
Sex: F
Vaccine: FLU3
Symptoms: Vaccination site rash
Clinical narrative: ON 10/14/2016 PATIENT CAME TO THE PHARMACY COMPLAINING OF A RASH ON HER ARM WHERE SHE RECEIVED THE VACCINE.
Age: 18.0
Sex: F
Vaccine: FLU4
Symptoms: Dizziness, Eye movement disorder, Flushing, Seizure
Clinical narrative: Patient reported she felt light-headed and become very flushed.  Patient then began to feel as if she would faint and laid back on a bench.  As she laid back, witnesses reported that patient began to briefly seize and her eyes rolled back into her head.  Patient quickly returned to normal and walked out of store with help.  It was recommended that patient's mother take her to ED to have her checked out.
Age: 73.0
Sex: M
Vaccine: FLU3
Symptoms: Body temperature increased, Chills, Feeling abnormal
Clinical narrative: Temperature 102, strange feeling of wonline $, chills.  2000 mg acetominepnine over 6 hours resulted in no fever, return to normal the next morning.
Age: 37.0
Sex: F
Vaccine: RAB
Symptoms: Injection site pruritus, Injection site rash, Injection site warmth
Clinical narrative: UPPER L ARM FELT HOT, RASH, ITCHY, DONOR DID NOT CONTACT CTR UNTIL 10/15/16. DONOR DID NOT TAKE ANY STEPS TO CARE FOR REACTION SITE.
Age: 52.0
Sex: M
Vaccine: TTOX, VARZOS
Symptoms: Blister, Discomfort, Herpes zoster, Pruritus, Rash erythematous
Clinical narrative: A patch of fairly intense shingles about 1.5 by 0.75 inches on chest, just below heart. Included blisters. Started to spread 10/15/2016 in a minor way, a few red spots on the side, same side as initial outbreak. Also itching, discomfort on back at approximately the same spot as on the front for the entire time. Returned to clinic on 10/15/2016 where shingles was confirmed.
Age: 54.0
Sex: F
Vaccine: PPV
Symptoms: Chills, Pain in extremity, Peripheral swelling
Clinical narrative: Swelling and pain from shoulder to elbow, chills, advised to treat with MOTRIN, BENADRYL, and cold packs and seek emergency treatment if no relief.
Age: 19.0
Sex: M
Vaccine: FLU3
Symptoms: Hot flush, Presyncope, Skin discolouration, Syncope, Visual impairment
Clinical narrative: PATIENT HAD SYNCOPE AFTER RECEVING THE AFLURIA INJECTION INTRAMUSCULARY. PATIENT REPORTED HOT FLASHES, VISUAL DISTURBANCES, AND ALMOST FAINTED. PATIENT WAS ASKED TO SIT IN THE CHAIR, AFTER ABOUT 10 MINUTES , HE REPORTED CLEARING VISION, RESTORED SKIN COLOR. PATIENT WAS ASKED TO LAY DOWN IN RELAXED POSITION FOR ABOUT 1 HOUR , BEFORE HE REPORTED RECOVERY FROM THE EPISODE.
Age: 55.0
Sex: F
Vaccine: FLUX
Symptoms: Dysarthria, Feeling abnormal, Headache, Hypertension, Thirst
Clinical narrative: Feeling bad, went to bed, work up with headache, slurred speech, couldn't speak correctly, high blood pressure all day.  Next morning improved.
Age: 5.0
Sex: F
Vaccine: FLU4
Symptoms: Fall, Loss of consciousness
Clinical narrative: A few minutes after receiving the vaccine the patient passed out and her father carried her back to the pharmacy. The father stated that she fell forward, and he picked her up. She was conscious when he picked her up and brought her back to the pharmacy.
Age: 29.0
Sex: F
Vaccine: FLU4
Symptoms: Conjunctivitis viral, Eye pruritus, Face oedema
Clinical narrative: Bilateral Facial Edema, Viral Conjunctivitis, Itchy eye (left).
Age: 17.0
Sex: M
Vaccine: MENB
Symptoms: Chills, Dyspnoea, Headache, Myalgia, Pyrexia
Clinical narrative: Headache, muscular pain, shivers, breathlessness and fever.
Age: 25.0
Sex: F
Vaccine: HPV9
Symptoms: Headache, Injection site pain, Insomnia, Muscle spasms, Musculoskeletal stiffness
Clinical narrative: I had pain when the injection was given. Five days later I had a headache, stiff neck, muscle spasms, and insomnia.
Age: 66.0
Sex: F
Vaccine: FLU3, PNC13
Symptoms: Condition aggravated, Feeling abnormal, Hypertension, Hypotension, Pneumonia
Clinical narrative: 10/1/16 PREVNAR was administered. On 10/3/16 Pt fell bad. 10/7/16 Pt went to see primary MD with fever and low B.P. She was sent to hospital DX pneumonia and HTN complication.
Age: 66.0
Sex: F
Vaccine: FLU3, PNC13
Symptoms: Pyrexia
Clinical narrative: 10/1/16 PREVNAR was administered. On 10/3/16 Pt fell bad. 10/7/16 Pt went to see primary MD with fever and low B.P. She was sent to hospital DX pneumonia and HTN complication.
Age: 65.0
Sex: F
Vaccine: FLU3
Symptoms: Erythema, Pain
Clinical narrative: Pt. reported on 10/13/16 (rec'd on 10/11/16) 3" area of redness, excessively "sore and painful. Give pt. Ibuprofen 200mg, BENADRYL 25mg and ice pk to alleviate symptoms.
Age: 71.0
Sex: F
Vaccine: FLU3
Symptoms: Asthenia, Chest pain, Fatigue, Malaise, Mobility decreased
Clinical narrative: Patient states that on the evening she received her flu vaccine she began to experience weakness in her arm that spread to more generalized weakness. Also had chest pain and fatigue. Says she was not able to leave bed for the 10 days following vaccine - never saw MD for x-ray/testing because she felt too ill to do so.
Age: 71.0
Sex: F
Vaccine: FLU3
Symptoms: Muscular weakness
Clinical narrative: Patient states that on the evening she received her flu vaccine she began to experience weakness in her arm that spread to more generalized weakness. Also had chest pain and fatigue. Says she was not able to leave bed for the 10 days following vaccine - never saw MD for x-ray/testing because she felt too ill to do so.
Age: 50.0
Sex: F
Vaccine: FLUX
Symptoms: Discomfort, Injection site erythema, Injection site pain, Injection site swelling, Injection site warmth
Clinical narrative: Patient presents with redness, warmth and increased swelling in (R) deltoid after influenza vaccination on 10/4/2016. She reports increased discomfort in last 24 hours. Patient has been taking BENADRYL and CLARITIN daily. Mild increased discomfort with direct pressure to the area. No radiation of pain down the arm. Pt advised to continue CLARITIN/BENADRYL. Advised 1XN to vaccination should be self limited. Will start MEDROL dose pack if no improvement in 3 days.
Age: 31.0
Sex: F
Vaccine: FLU4
Symptoms: Hypoaesthesia, Hypoaesthesia oral, Paraesthesia oral, Vision blurred
Clinical narrative: Pt said about an hr after she got the shot she got blurry vision then numbness in her hand/arm then numbness/tingling in mouth/tongue.
Age: 67.0
Sex: F
Vaccine: FLU3, PPV
Symptoms: Injection site erythema, Injection site pain, Injection site swelling, Pyrexia
Clinical narrative: Red, painful, swollen area at injection site. Moderate fever (101-102 degrees) per patient, same day and next day.
Age: 80.0
Sex: M
Vaccine: FLU3
Symptoms: Injection site bruising, Injection site swelling, Malaise, Pain, Pain in extremity
Clinical narrative: Swelling and some bruising of upper right arm and right hand and finger pain generalized pain and malaise and about 8 hours after vaccination-continued into next day.
Age: 18.0
Sex: F
Vaccine: FLU3
Symptoms: Loss of consciousness
Clinical narrative: About a minute after the administration of a Flu shot, pt. lost consciousness for about 3-5 min. We put her feet up and cold pack on her face. Mom made her drink fluid and she recovered quickly and walk out to go home.
Age: 4.0
Sex: U
Vaccine: DTAPIPV, FLU4, MMRV
Symptoms: Injection site erythema, Injection site pain, Injection site swelling
Clinical narrative: Pain, redness, swelling to injection site Lt deltoid. Treated with Cephalexin and BENADRYL.
Age: 13.0
Sex: F
Vaccine: FLU4
Symptoms: Anxiety, Depressed level of consciousness, Emotional distress, Muscle rigidity, Staring
Clinical narrative: Approximately 3 minute after vaccination, pt was not alert for approximately 30 seconds. Arms became very rigid. Eyes were open at all times, but she but she became alert after 30 seconds but was under anxiety/distress - 20-25 minutes to recover.
Age: 90.0
Sex: U
Vaccine: FLU3
Symptoms: Erythema, Inflammation, Pain in extremity
Clinical narrative: 10/14 Inflammation, redness, pain to the elbow. 10/15 same symptoms no bruising.
Age: 3.0
Sex: M
Vaccine: FLU4
Symptoms: Cellulitis, Erythema of eyelid, Eyelid oedema, Injection site erythema, Injection site swelling
Clinical narrative: Had swollen red arm on left arm x 2 days, now resolved but (R) upper lid red and swollen. Cellulitis and being TX.
Age: 54.0
Sex: F
Vaccine: FLU3, TDAP
Symptoms: Injection site bruising, Injection site pain
Clinical narrative: 2x4 inch bruise surrounding inj site. Pt said bruise started day after inj. She came to me today. Described as sore.
Age: 72.0
Sex: M
Vaccine: FLU3
Symptoms: Erythema, Infection, Inflammation, Swelling
Clinical narrative: Redness, swelling, inflammation. Visited Dr. Per patient MD prescribed KEFLEX 500 mg three times daily #21. (Per patient infection - according to MD).
Age: 59.0
Sex: M
Vaccine: FLU3
Symptoms: Chills, Vomiting
Clinical narrative: Pt states hours after receiving the vaccine he started having chills and vomited for several hours. He reports having these symptoms in the past after receiving the flu vaccine. Advised pt to discuss future administration w/PCP.
Age: 74.0
Sex: F
Vaccine: FLU4, PPV
Symptoms: Injection site erythema, Injection site pain, Injection site swelling, Pain in extremity, Pyrexia
Clinical narrative: Fever (102 degrees F) started approximately 5 hrs post vaccine and redness swelling at site of injection. Painful to touch and worsening over next couple of days. Fever has come down. Entire arm aches.
Age: 68.0
Sex: F
Vaccine: FLU3, PNC13
Symptoms: Erythema, Headache, Neck pain, Pain in extremity, Urticaria
Clinical narrative: Patient described welps down her arm, migraine like pain in head and neck and neck that was not migraine per patient. Local redness and pain redness down arm, lasting 3 days then resolving. Symptoms began about 30 min after shot.
Age: 69.0
Sex: F
Vaccine: FLU3
Symptoms: Erythema, Infection, Inflammation, Pruritus, Swelling
Clinical narrative: Redness, swelling, itching, inflammation. Visited Dr. MD prescribed KEFLEX 500mg three times daily #21 (per patient infection).
Sex: U
Vaccine: HPV9
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 16-MAY-2016 the patient was vaccinated with an improperly stored dose of GARDASIL 9 0.5 ml (lot # L038917, expiration date 20-FEB-2018, route unspecified). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 120 hours with the lowest recorded temperature of 34 Fahrenheit degree. The total cumulative excursion time of the second time was 72 hours with the lowest recorded temperature of 32 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effect reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: HPV4
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 18-JUL-2016 the patient was vaccinated with an improperly stored dose of GARDASIL (lot # L040460, expiration date 27-MAY-2017, dose and route were unspecified). This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time was 80 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 12-MAY-2015 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 0.5ml (lot # K012424, expiration date 05-JUN-2016). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 24 hours with the lowest recorded temperature of -1 Fahrenheit degree. The total cumulative excursion time of the second time was 48 hours with the lowest recorded temperature of 0 Fahrenheit degree. The storage criteria and the type of excursion was refrigerator (R). No adverse effects were reported. This is one of several reports received form the same source. Additional information has been requested.
Sex: U
Vaccine: HEPA
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 09-DEC-2014 the patient was vaccinated with an improperly stored dose of VAQTA 50unit/ml (lot # J001396, expiration date 02-AUG-2015, dose and route unknown). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 48 hours with the lowest recorded temperature of 1 Fahrenheit degree. The total cumulative excursion time of the second time was 72 hours with the highest recorded temperature of 9 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse event was reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager via two company representatives referring to a patient of unknown age and gender. The patient's medical history, concurrent condition and concomitant medication were unknown. On 21-DEC-2015 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 0.5 ml (lot # L010598, expiration date 06-AUG-2016, route unknown). This specified lot number vaccine was exposed to temperature excursion fourteen times. The total cumulative excursion time (hour) and lowest recorded temperature (Fahrenheit degree) for each time were as below: (216, 29.3); (144, 34.2); (24, 33.6); (24, 33.4); (52, 33.1); (72, 32.9); (144, 32.4); (100, 34.5); (28, 30); (24, 34.3); (48, 34.9); (36, 31.1); (104, 29.1); (24, 34.8). The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager via company representative referring to a patient of unknown age and gender. On 14-APR-2015 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23-10PK-0.5mlSD-PFS LLokwTip) (lot # K019386, expiration date 09-JUN-2016). This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time was 864 hours with the lowest recorded temperature of 27 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 08-SEP-2015, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 0.5ml (lot # K012424, expiration date 05-JUN-2016). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 24 hours with the lowest recorded temperature of -1 Fahrenheit degree. The total cumulative excursion time of the second time was 48 hours with the lowest recorded temperature of 0 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: HEPA
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 08-JAN-2015 the patient was vaccinated with an improperly stored dose of VAQTA 50unit/ml (lot # J001396, expiration date 02-AUG-2015, dose and route unknown). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 72 hours with the highest recorded temperature of 9 Fahrenheit degree. The total cumulative excursion time of the second time was 48 hours with the lowest recorded temperature of 1 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse event was reported. This is one of several reports received from the same source. Additional information has been requested.
Age: 76.0
Sex: M
Vaccine: PPV
Symptoms: Erythema, Injection site pain, Injection site rash
Clinical narrative: Pt reported rash and soreness around the site of injection. Rash decreased in 1 day but still red lower region of side arm.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager via company representative referring to a patient of unknown age and gender. On 12-MAR-2015 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23-10PK-0.5mlSD-PFS LLokwTip) (lot # K019386, expiration date 09-JUN-2016). This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time was 1536 hours with the lowest recorded temperature of 27 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: HPV4
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 02-MAY-2016 the patient was vaccinated with an improperly stored dose of GARDASIL (lot # L040460, expiration date 27-MAY-2017, dose and route were unspecified). This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time was 80 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager via company representative referring to a patient of unknown age and gender. On 10-APR-2015 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23-10PK-0.5mlSD-PFS LLokwTip) (lot # K019386, expiration date 09-JUN-2016). This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time was 768 hours with the lowest recorded temperature of 27 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: RV5
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 16-NOV-2015 the patient was vaccinated with an improperly stored dose of ROTATEQ oral dose, 10-pack (lot # K010224, expiration date 13-MAY-2016) orally. This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time was 288 hours with lowest recorded temperature of 1.11 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager via two company representatives referring  to a patient of unknown age and gender. The patient's medical history, concurrent condition and concomitant medication were unknown. On 29-DEC-2015 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 0.5 ml (lot # L010598, expiration date 06-AUG-2016, route unknown). This specified lot number vaccine was exposed to temperature excursion fourteen times. The total cumulative excursion time (hour) and lowest recorded temperature (Fahrenheit degree) for each time were as below: (216, 29.3); (144, 34.2); (24, 33.6); (24, 33.4); (52, 33.1); (72, 32.9); (144, 32.4); (100, 34.5); (28, 30); (24, 34.3); (104, 29.1); (38, 34.9); (36, 1.1); (24, 34.8). The storage criteria and type of excursion for this vaccine was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: MMR
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 12-JUN-2014, the patient was vaccinated with an improperly stored dose of M-M-R II 0. 5ml, (HSA, lot # J006995, expiration date 14-JUN-2015). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time was 40 hours with the highest recorded temperature of 6 Fahrenheit degree. The storage criteria were refrigerator/freezer (R/F) and the type of excursion for this vaccine was freezer (F). This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. The patient's medical history, concurrent condition and concomitant therapy were not provided. On 28-JUN-2016, the patient was vaccinated with an improperly  stored dose of PNEUMOVAX 23 "10PK-0.5 ml SD-PFS LLok wTip" (lot # M005286, expiration date: 08-OCT-2017, dose and route were unspecified). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 304 hours with the lowest recorded temperature of 33 Fahrenheit degree. The total cumulative excursion time of the second time was 40 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: MMR
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 07-JAN-2015 the patient was vaccinated with an improperly stored dose of M-M-R II 0.5ml, (HSA, lot # J006995, expiration date 14-JUN-2015). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion six times. The total cumulative excursion time of the first time was 344 hours with the highest recorded temperature of 6 Fahrenheit degree. The total cumulative excursion time of the second time was 160 hours with the highest recorded temperature of 10 Fahrenheit degree. The total cumulative excursion time of the third time was 48 hours with the lowest recorded temperature of 34 Fahrenheit degree. The total cumulative excursion time of the fourth time was 64 hours with the highest recorded temperature of 17 Fahrenheit degree. The total cumulative excursion time of the fifth time was 40 hours with the highest recorded temperature of 47 Fahrenheit degree. The total cumulative excursion time of the sixth time was 72 hours with the lowest recorded temperature of 28 Fahrenheit degree. The storage criteria were refrigerator/freezer (R/F) and the type of excursion for this vaccine of the first, second and fourth time) was freezer (F); the type of excursion for this vaccine of the other times was refrigerator (R). This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: MMR
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 19-FEB-2015, the patient was vaccinated with an improperly stored dose of M-M-R II 0.5ml, (HSA, lot # J006995, expiration date 14-JUN-2015). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion eight times. The total cumulative excursion time of the first time was 160 hours with highest recorded temperature of 10 Fahrenheit degree. The total cumulative excursion time of the second time was 344 hours with the highest recorded temperature of 6 Fahrenheit degree. The total cumulative excursion time of the third time was 40 hours with the highest recorded temperature of 8 Fahrenheit degree. The total cumulative excursion time of the fourth time was 64 hours with the highest recorded temperature of 17 Fahrenheit degree. The total cumulative excursion time of the fifth time was 40 hours with the highest recorded temperature of 47 Fahrenheit degree. The total cumulative excursion time of the sixth time was 176 hours with the lowest recorded temperature of 32 Fahrenheit degree. The total cumulative excursion time of the seventh time was 48 hours with the lowest recorded temperature of 34 Fahrenheit degree. The total cumulative excursion time of the eighth time was 72 hours with the lowest recorded temperature of 28 Fahrenheit degree. The storage criteria were refrigerator/freezer (R/F) and the type of excursion for this vaccine (from 1st time to fourth time) was freezer (F); the type of excursion for this vaccine (from the fifth time to eighth time) was refrigerator (R). This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: MMR
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 17-OCT-2014, the patient was vaccinated with an improperly stored dose of M-M-R II 0.5ml, (HSA, lot # J006995, expiration date 14-JUN-2015). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion five times. The total cumulative excursion time of the first time was 64 hours with the highest recorded temperature of 17 Fahrenheit degree. The total cumulative excursion time of the second time was 72 hours with the lowest recorded temperature of 28 Fahrenheit degree. The total cumulative excursion time of the third time was 40 hours with the highest recorded temperature of 47 Fahrenheit degree. The total cumulative excursion time of the fourth time was 240 hours with the highest recorded temperature of 6 Fahrenheit degree. The total cumulative excursion time of the fifth time was 32 hours with the highest recorded temperature of 10 Fahrenheit degree. The storage criteria were refrigerator/freezer (R/F) and the type of excursion for this vaccine (the second and third time) was refrigerator (R); the type of excursion for this vaccine of the other times was freezer (F). This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: MMR
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician via company employees and a practice manager referring to a patient of unknown age and gender. On 11-FEB-2015 the patient was vaccinated with an improperly stored dose od M-M-R II 0.5ml, lot # J014876, expiration date 21-NOV-2015, dose and route were unspecified). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 3156 hours with the lowest recorded temperature of 20 Fahrenheit degree. The total cumulative excursion of the second time was 1020 hours with the lowest recorded temperature of 27 Fahrenheit degree. The storage criteria of this vaccine was refrigerator/freezer (R/F) and the type of excursion was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. The patient's medical history, concurrent condition and concomitant therapy were not provided. On 23-MAY-2016, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 "10PK-0.5 ml SD-PFS LLok wTip" (lot # M005286, expiration date: 08-OCT-2017, dose and route were unspecified). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time was 120 hours with the lowest recorded temperature of 33 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: MMR
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician via company employees and a practice manager referring to a patient of unknown age and gender. On 12-FEB-2015 the patient was vaccinated with an improperly stored dose of M-M-R II 0.5ml (rHA (recombinant human albumin), lot #J014876, expiration date 21-NOV-2015, dose and route were unspecified). This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time was 48 hours with the lowest recorded temperature of 32 Fahrenheit degree. The storage criteria of this vaccine was refrigerator/freezer (R/F) and the type of excursion was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 02-OCT-2014 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 (strength: 0.5ml, lot # K004281, expire date 22-MAR-2015; dose and route unknown). The total cumulative excursion time was 1368 hours with the lowest recorded temperature of 20 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: MMR
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 03-MAR-2015, the patient was vaccinated with and improperly stored dose of (wistar ra 27-3) M-M-R II 0.5ml, (HSA, lot # J006995, expiration date 14-JUN-2015). No adverse effects were reported. The specified lot number vaccine was exposed to temperature excursion eight times. The total cumulative excursion time of the first time was 304 hours with the lowest recorded temperature of 32 Fahrenheit degree. The total cumulative excursion time of the second time was 344 hours with the highest recorded temperature of 6 Fahrenheit degree. The total cumulative excursion time of the third time was 40 hours with the highest recorded temperature of 8 Fahrenheit degree. The total cumulative excursion time of the fourth time was 160 hours with the highest recorded temperature of 10 Fahrenheit degree. The total cumulative excursion time of the sixth time was 72 hours with the lowest recorded temperature of 28 Fahrenheit degree. The total cumulative excursion time of the seventh time was 40 hours with the highest recorded temperature of 47 Fahrenheit degree. The total cumulative excursion time of the eighth time was 48 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria were refrigerator/freezer (R/F) and the type of excursion for this vaccine (from the second time to fifth time) was freezer (F); the type of excursion for this vaccine of the other times was refrigerator (R). This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 24-SEP-2014 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 (strength: 0.5ml, lot # K004281, expire date 22-MAR-2015; dose and route unknown). The total cumulative excursion time was 1176 hours with the lowest recorded temperature of 20 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. The patient's medical history, concurrent condition and concomitant therapy were not provided. On 09-MAY-2016, the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 "10PK-0.5 ml SD-PFS LLok wTip (lot # M005286, expiration date: 08-OCT-2017, dose and route were unspecified). No adverse effects were reported. This specified lot number vaccine was exposed to temperature excursion once. The total cumulative excursion time was 8 hours with the lowest recorded temperature of 33 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: HPV9
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 05-JUL-2016 the patient was vaccinated with an improperly stored dose of GARDASIL 9 0.5ml (lot # L038917, expiration date 20-FEB-2018, route unspecified). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 72 hours with the lowest recorded temperature of 32 Fahrenheit degree. The total cumulative excursion time of the second time was 144 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effect reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: HEPA
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 22-JAN-2015 the patient was vaccinated with an improperly stored dose of VAQTA 50 unit/ml (lot # J001396, expiration date 02-AUG-2015, dose and route unknown). This specified lot number vaccine was exposed to temperature excursion three times. The total cumulative excursion time of the first time was 8 hours with the lowest recorded temperature of -1 Fahrenheit degree. The total cumulative excursion time of the second time was 72 hours with the highest recorded temperature of 9 Fahrenheit degree. The total cumulative excursion time of the third time was 48 hours with the lowest recorded temperature of 1 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse event was reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager via two company representatives referring to a patient of unknown age and gender. The patient's medical history, concurrent condition and concomitant medication were unknown. On 05-OCT-2015 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 0.5 ml (lot # L010598, expiration date 06-AUG-2016, route unknown). This specified lot number vaccine was exposed to temperature excursion fifteen times. The total cumulative excursion time (hour) and lowest recorded temperature (Fahrenheit degree) for each time were as below: (216, 29.3); (24, 33.6); (52, 33.1); (28, 30); (104, 29.1); (48, 32.9); (36, 31.1); (24, 34.5); (24, 32.4); (96, 34.2). The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effects were reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: HPV9
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 16-JUN-2016 the patient was vaccinated with an improperly stored dose of GARDASIL 9 0.5ml (lot # L038917, expiration date 20-FEB-2018, route unspecified). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 72 hours with the lowest recorded temperature of 32 Fahrenheit degree. The total cumulative excursion time of the second time was 144 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effect reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: HEPA
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 29-MAR-2014 the patient was vaccinated with an improperly stored dose of VAQTA 50unit/ml (lot # J001396, expiration date 02-AUG-2015, dose and route unknown). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 248 hours with the lowest recorded temperature of 34 Fahrenheit degree. The total cumulative excursion time of the second time was 408 hours with the lowest recorded temperature of 33 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse event was reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: HPV9
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 17-MAY-2016 the patient was vaccinated with an improperly stored dose of GARDASIL 9 0.5ml (lot # L038917, expiration date 20-FEB-2018, route unspecified). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 72 hours with the lowest recorded temperature of 32 Fahrenheit degree. The total cumulative excursion time of the second time was 136 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse effect reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: PPV
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 13-JUL-2016 the patient was vaccinated with an improperly stored dose of PNEUMOVAX 23 (lot # L040178, expiration date 18-AUG-2017). This specified lot number vaccine was exposed to temperature excursion one time. The total cumulative excursion time was 48 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R). No adverse event was reported. This is one of several reports received from the same source. Additional information has been requested.
Sex: U
Vaccine: HPV9
Symptoms: Incorrect product storage, No adverse event
Clinical narrative: Information has been received from a physician and a practice manager referring to a patient of unknown age and gender. On 28-JUN-2016 the patient was vaccinated with an improperly stored dose of GARDASIL 9 0.5ml, (lot # L038917, expiration date 20-FEB-2018, route unspecified). This specified lot number vaccine was exposed to temperature excursion twice. The total cumulative excursion time of the first time was 304 hours with the lowest recorded temperature of 33 Fahrenheit degree. The total cumulative excursion time of the second time was 40 hours with the lowest recorded temperature of 34 Fahrenheit degree. The storage criteria and the type of excursion for this vaccine was refrigerator (R).  No adverse effect was reported. This is one of several reports received from the same source. Additional information has been requested.